Upadacitinib for treating severe rheumatoid arthritis: Final appraisal document

In DRAFT guidance, NICE recommends upadacitinib with methotrexate (or as monotherapy in those who cannot take methotrexate) for the treatment of severe active RA in adults who meet the stated criteria, if the company provides it according to the commercial arrangement.

Source:

National Institute for Health and Care Excellence